Clinical profile, treatment and outcome of present cases with previously published cases
| Ref no | Age | Sex | Respiratory symptoms | Others | Outcome |
| 14 | 68 | F | Unusual dyspnoea | NA | Improved |
| 15 | 58 | F | NA | mPSL, PSL, IVCY, IVIg,PMX | Improved |
| 16 | 55 | F | Respiratory failure | CPA, PE | Died |
| 17 | 71 | F | Respiratory failure | PSL, Tac | improved |
| 18 | 71 | F | Respiratory failure | mPSL, PSL, CsA, MMF, Tac | Died |
| 18 | 69 | F | Respiratory failure | mPSL, PSL, CsA, IVCY, tocilizumab, CHD PSL, | Died |
| 19 | 48 | M | Respiratory failure | PSL, CsA | Improved |
| Present case1 | 37* | F | Respiratory failure | mPSL, RTX, IVIg | Died |
| Present case2 | 42* | F | Respiratory failure | mPSL, RTX | Died |
CHD, continuous hemodiafiltration; CPA, cyclophosphamide; CsA, Ciclosporin A; F, female; IVCY, intravenous cyclophosphamide; M, male; MMF, mycophenolate mofetil; mPSL, methylprednisolone; NA, not available; PE, plasma exchange; PMX, polymyxin B; PSL, prednisolone; RTX, rituximab; Tac, tacrolimus.